The future of immuno-oncology in kidney cancer

In his keynote lecture at the American Society for Clinical Oncology Genitourinary (ASCO GU) 2018 meeting in San Francisco this month, Dr Bernard Escudier from the Institut Gustave Roussy in Villejuif, France, discussed the future of immuno-oncology in renal cell carcinoma (RCC). The current landscape of immune-oncology has been shaped by the results from the […]

read more

Combination immunotherapy: the new standard of care for metastatic kidney cancer

The following video interviews discuss combinations of immunotherapy drugs and immunotherapy plus targeted therapy for the first-line treatment of metastatic renal cell carcinoma (RCC). Sumanta K. Pal, MD, of the City of Hope National Medical Center in California, USA discusses immunotherapy as a first-line treatment for kidney cancer and the strategy of VEGF blockade with […]

read more

The benefits of immunotherapy combinations

This article, published in Nature just before Christmas, gives a good overview of the use of combinations of immunotherapy drugs to fight cancer. Immunotherapies trigger the immune system causing a self-sustaining attack against cancer cells by immune cells known as T cells, producing long-term clinical benefits, and, in some cases, a cure. Around 2,000 immunotherapy […]

read more

Lenvatinib plus pembrolizumab combination designated a breakthrough therapy by the FDA

The US Food and Drug Administration (FDA) have granted Breakthrough Therapy Designation for the multiple receptor tyrosine kinase inhibitor, lenvatinib (Kisplyx) in combination with the anti-PD-1 therapy, pembrolizumab (Keytruda) for the treatment of patients with advanced and/or metastatic renal cell carcinoma (RCC). The breakthrough therapy designation speeds up the development and review of medicines that […]

read more

European guidelines for the management of metastatic renal cell carcinoma to be updated

The European Association of Urology (EAU) guidelines are to be updated based on the results of the phase III Checkmate-214 clinical trial, which change the first-line standard treatment for metastatic renal cell carcinoma (RCC). The trial showed superior survival for a combination of ipilimumab and nivolumab, compared with the previous standard of care, in intermediate- […]

read more

Positive interim results for atezolizumab plus bevacizumab combination in advanced RCC

Interim results from the phase III IMmotion151 study to assess a combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) for advanced or metastatic renal cell carcinoma (RCC) have been reported to have improved progression-free survival (PFS), compared to sunitinib (Sutent) as a first-line treatment. The researchers said that the combination provided a statistically significant and clinically […]

read more

Statins may be used to treat kidney cancer in combination with anticancer drugs

A recent study by researchers in Greece and published in¬†OncoTargets and Therapy suggests that statins could possibly benefit kidney cancer patients when used in combination with anticancer drugs. The researchers report that high cholesterol levels and the growth of tumours are interrelated, and studies are now warranted to investigate whether some statins should be part […]

read more

New combination treatment shows promise in kidney cancer

Results from a phase I clinical trial with a combination of X4P-001-IO plus axitinib in patients with clear cell renal cell carcinoma (ccRCC) were presented at the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain this week. The early phase results demonstrated encouraging disease control rates and durable responses with the new […]

read more

Lenvatinib plus pembrolizumab combination shows promise in advanced kidney cancer

Interim results from Study 111, a phase Ib/II clinical trial exploring the potential of a combination of lenvatinib (Kisplyx), a tyrosine kinase inhibitor (TKI), plus pembrolizumab (Keytruda), a PD-1 inhibitor, in patients with solid tumours, were presented at the European Society of Medical Oncology (ESMO) conference in Madrid, Spain this week. The results presented for […]

read more

Mixed results for nivolumab/ipilimumab combination in advanced kidney cancer

The results from the recent phase III CheckMate-214 clinical trial comparing a combination of nivolumab (Opdivo) and ipilimumab (Yervoy) with sunitinib (Sutent) was not successful in meeting one of its primary objectives; the nivolumab/ipilimumab combination failed to significantly improve progression-free survival (PFS) compared to sunitinib in intermediate and poor-risk patients with previously untreated advanced or […]

read more
Showing 121 to 130 of 133 results
  TOP